Roche announced the launch of three molecular PCR diagnostic test panels to simultaneously detect and differentiate common respiratory pathogens: influenza A, influenza B and respiratory syncytial virus (RSV), adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV), parainfluenza 1, 2, 3 and 4. The three tests can be run together or individually from a single nasopharyngeal swab specimen. As respiratory viruses circulating within a community can vary depending on seasonality and geography, a flexible testing option based on a syndromic-style panel enables personalised healthcare and helps reduce unnecessary testing. Patients with respiratory infections often have signs and symptoms that are indicative of the disease, but are not specific enough to discern the root cause of the illness. Syndromic testing allows clinicians to test patients simultaneously for multiple pathogens based on overlapping symptoms. By detecting the most common pathogens that cause disease on a flexible set of test panels together, clinicians are provided with actionable insights so the right therapeutic can be prescribed sooner compared to conventional test methods. This in turn enables timely infection control, proper hospital bed management and improved patient care. These new respiratory test panels run on the cobasomni Utility Channel for use with the widely available, high-volume cobas® 6800/8800 Systems, which have proven to bring reliable results quickly to meet the urgent demand for patient testing during the COVID-19 pandemic. Addition of these tests will equip health systems to combat new respiratory diseases when they arise. Roche is looking to expand availability of these tests beyond CE markets in the future.